3 years 18
Extreme 18
62
5 years 13.6
Extreme 13.6
77.7
10 years 13.6
Extreme 13.6
96.48
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/01/2023
Compliance Officer - 01/01/2022
Investor Relations Contact - 01/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/25 Issuer sale

Director

85,011 0.1134%
01/07/25 Issuer sale

Chief Financial Officer

7,38,955 0.9861%
01/07/25 Issuer sale

Chief Technology Officer

1,51,946 0.2028%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%-.--% - - 354.06Cr
+3.62%+1.68%+48.80%+98.41% 1,04000Cr
+2.13%-1.76%+33.04%+61.88% 60TCr
+3.32%+4.47%+23.72%+91.59% 48TCr
+3.80%+3.21%+73.99%+41.69% 35TCr
+3.09%+3.03%+29.59%+45.42% 35TCr
+2.82%+2.20%+17.90%+40.15% 27TCr
+3.40%+0.99%-3.44%+12.08% 24TCr
+3.21%+3.15%+45.01%+49.99% 22TCr
+3.80%+4.56%+29.59%+97.73% 18TCr
Average +2.72%+1.90%+33.13%+59.88% 41.59TCr
Weighted average by Cap. +2.66%+1.53%+36.79%+68.68%
Logo SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.
Employees
368
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - SpringWorks Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. SWTX Stock